Instrumento Inactivo

Otros idiomas Synthetic Biologics Inc Nyse

Acciones

US87164U1025

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Theriva Biologics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	07/05
Theriva™ Biologics Reports First Quarter 2024 Operational Highlights and Financial Results	07/05
Theriva™ Biologics to Discuss the Trial Design for VIRAGE - a Phase 2b Clinical Study of Systemically Administered VCN-01 in Combination with Chemotherapy in Pancreatic Ductal Adenocarcinoma - at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting	25/04
Theriva™ Biologics Announces Positive Topline Data from Investigator Sponsored Phase 1 Trial of Intravitreal VCN-01 in Pediatric Patients with Refractory Retinoblastoma	23/04
Theriva Biologics Announces Positive Topline Data from Investigator Sponsored Phase 1 Trial of Intravitreal VCN-01 in Pediatric Patients with Refractory Retinoblastoma	23/04
Theriva™ Biologics to Present Preclinical Data Supporting the Potential Synergy of VCN-01 and First-Line Pancreatic Cancer Chemotherapy Regimens at the American Society for Cell and Gene Therapy 27th Annual Meeting	22/04
Theriva™ Biologics Announces Presentation at the American Society for Cell and Gene Therapy 27th Annual Meeting	08/04
Theriva™ Biologics Reports Full-Year 2023 Operational Highlights and Financial Results	25/03
Theriva Biologics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	25/03
North American Morning Briefing : Tech in Focus on -2-	25/03
Theriva™ Biologics to Host Conference Call and Webcast to Discuss Full Year 2023 Operational Highlights and Financial Results	19/03
Theriva™ Biologics to Participate in the BIO-Europe Spring Conference	11/03
Theriva Biologics Announces Positive Recommendation from the Independent Data Monitoring Committee of VIRAGE, the Phase 2b Clinical Trial of VCN-01 in Combination with Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma	07/02
Theriva Biologics Announces Positive Recommendation from the Independent Data Monitoring Committee of VIRAGE, the Phase 2b Clinical Trial of VCN-01 in Combination with Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma	07/02
Theriva Biologics to Participate in the B. Riley Securities Annual Oncology Conference	16/01
Theriva Biologics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	13/11
Theriva™ Biologics Reports Third Quarter 2023 Operational Highlights and Financial Results	13/11
North American Morning Briefing : Stock Futures -2-	13/11
Theriva Biologics to Host Conference Call and Webcast to Discuss Third Quarter 2023 Operational Highlights and Financial Results	06/11
Theriva™ Biologics to Participate in the BIO-Europe Conference	02/11

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Synthetic Biologics Inc Nyse

Acciones

US87164U1025

Otros idiomas

Filtros